Latest Ratios: P/E Ratio -3.5x · EV/EBITDA 395.5x · ROE -12.4%. (2000–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $377M | $301M | $417M | $406M | $230M | $819M | $1.2B | $606M | $231M | $141M | $133M |
| Enterprise Value | $690M | $614M | $656M | $675M | $577M | $1.1B | $1.2B | $566M | $333M | $233M | $227M |
| P/E Ratio → | -3.45 | — | — | — | — | — | 283.37 | 75.00 | 90.07 | — | — |
| P/S Ratio | 0.52 | 0.41 | 0.63 | 0.69 | 0.45 | 1.69 | 2.71 | 1.48 | 0.83 | 0.59 | 0.54 |
| P/B Ratio | 0.44 | 0.36 | 0.46 | 0.43 | 0.23 | 0.74 | 1.73 | 1.19 | 0.72 | 0.68 | 0.71 |
| P/FCF | — | — | — | — | — | — | — | 181.48 | 7.58 | 32.38 | 9.53 |
| P/OCF | 72.16 | 57.61 | 59.44 | — | — | — | 824.52 | 25.94 | 5.16 | 7.80 | 6.19 |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 0.84 | 0.99 | 1.14 | 1.13 | 2.30 | 2.68 | 1.38 | 1.20 | 0.97 | 0.93 |
| EV / EBITDA | 395.46 | 351.84 | — | — | — | — | 42.78 | 13.08 | 10.49 | 9.15 | 8.79 |
| EV / EBIT | — | — | — | — | — | — | — | 76.92 | 33.21 | 58.93 | 105.13 |
| EV / FCF | — | — | — | — | — | — | — | 169.46 | 10.94 | 53.68 | 16.25 |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 38.8% | 38.8% | 43.9% | 41.3% | 36.9% | 38.6% | 41.8% | 48.1% | 46.0% | 42.4% | 45.2% |
| Operating Margin | -9.1% | -9.1% | -13.9% | -18.2% | -30.9% | -24.5% | -3.1% | 3.2% | 3.6% | 1.2% | 1.1% |
| Net Profit Margin | -14.9% | -14.9% | -11.9% | -14.9% | -28.3% | -1.7% | 0.9% | 2.0% | 1.0% | -0.2% | -2.5% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -12.4% | -12.4% | -8.5% | -9.1% | -13.7% | -0.9% | 0.7% | 1.9% | 1.0% | -0.2% | -2.9% |
| ROA | -7.2% | -7.2% | -4.7% | -5.1% | -8.0% | -0.6% | 0.5% | 1.3% | 0.6% | -0.1% | -1.7% |
| ROIC | -4.3% | -4.3% | -5.9% | -6.3% | -8.6% | -8.5% | -1.8% | 2.2% | 2.1% | 0.8% | 0.7% |
| ROCE | -5.1% | -5.1% | -6.3% | -6.7% | -9.2% | -8.8% | -1.8% | 2.4% | 2.7% | 1.0% | 0.9% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.56 | 0.56 | 0.67 | 0.65 | 0.61 | 0.55 | 0.31 | 0.26 | 0.35 | 0.51 | 0.57 |
| Debt / EBITDA | 270.65 | 270.65 | — | — | — | — | 7.82 | 3.07 | 3.53 | 4.14 | 4.12 |
| Net Debt / Equity | — | 0.37 | 0.26 | 0.29 | 0.35 | 0.27 | -0.02 | -0.08 | 0.32 | 0.45 | 0.50 |
| Net Debt / EBITDA | 179.17 | 179.17 | — | — | — | — | -0.38 | -0.93 | 3.23 | 3.63 | 3.63 |
| Debt / FCF | — | — | — | — | — | — | — | -12.02 | 3.36 | 21.30 | 6.72 |
| Interest Coverage | -17.61 | -17.61 | -11.19 | -13.06 | -20.02 | -14.45 | -1.00 | 1.98 | 1.61 | 0.71 | 0.22 |
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 4.26 | 4.26 | 1.98 | 6.20 | 6.73 | 7.81 | 6.13 | 4.55 | 1.70 | 2.42 | 1.32 |
| Quick Ratio | 3.94 | 3.94 | 1.89 | 5.95 | 6.46 | 7.54 | 5.73 | 4.32 | 1.56 | 2.21 | 1.21 |
| Cash Ratio | 1.81 | 1.81 | 1.28 | 4.31 | 4.87 | 5.91 | 4.05 | 2.71 | 0.16 | 0.37 | 0.21 |
| Asset Turnover | — | 0.53 | 0.40 | 0.35 | 0.29 | 0.26 | 0.45 | 0.58 | 0.55 | 0.70 | 0.72 |
| Inventory Turnover | 15.57 | 15.57 | 13.85 | 14.37 | 13.26 | 12.71 | 8.76 | 14.72 | 17.28 | 18.50 | 21.38 |
| Days Sales Outstanding | — | 79.91 | 83.18 | 80.98 | 85.72 | 84.50 | 87.74 | 85.03 | 101.45 | 91.80 | 83.01 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | 0.4% | 1.3% | 1.1% | — | — |
| FCF Yield | — | — | — | — | — | — | — | 0.6% | 13.2% | 3.1% | 10.5% |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 21.7% | 0.0% | 41.4% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 21.7% | 0.0% | 41.4% |
| Shares Outstanding | — | $26M | $25M | $25M | $25M | $24M | $22M | $21M | $18M | $16M | $16M |
Persistent Operating Margin Deficit
Based on current market data, NeoGenomics trades at a price-to-sales ratio of 0.51, which appears to discount the company's inability to achieve consistent profitability compared to higher-multiple peers like Natera, suggesting investors are prioritizing revenue stability over the current lack of bottom-line earnings generation.
The forward P/E of 78.72 indicates that the market is pricing in a significant recovery in earnings, yet the negative TTM P/E highlights the current reality of operational losses. This valuation gap suggests that the market remains skeptical of the company's ability to scale its specialized oncology services into a profitable enterprise without further dilutive capital raises.
As reported in financial statements, NeoGenomics has consistently generated negative ROIC, with the most recent quarter at -1.2%, indicating that the company is currently destroying shareholder value rather than compounding it through its heavy investments in laboratory infrastructure and specialized diagnostic personnel.
The persistent negative return on capital suggests that the company's asset base, heavily weighted toward goodwill from past acquisitions, is not generating sufficient returns to cover the cost of capital. This trend warrants further investigation into whether the current diagnostic testing mix can ever achieve the margins necessary to justify the capital intensity of the business.
According to recent quarterly filings, the company's cash conversion cycle remains elevated at 83 days, driven by a persistent DSO of 79 days, which suggests that NeoGenomics faces significant friction in its billing and collection processes within the fragmented US oncology payer environment.
The inability to meaningfully compress the cash conversion cycle indicates that the company's working capital management is a structural drag on liquidity. Investors should monitor whether these collection delays are a permanent feature of the reimbursement landscape or if operational improvements can accelerate cash inflows.
Based on reported figures, NeoGenomics has reduced its debt-to-equity ratio to 0.49 as of 2026Q1, a prudent move that appears to be a response to the ongoing cash burn and the lack of consistent operating income to service higher debt levels.
While the reduction in leverage is a positive signal for balance sheet stability, the negative interest coverage ratio suggests that the company remains vulnerable to any tightening in credit conditions. The current debt profile appears manageable only if the company can successfully pivot toward positive free cash flow in the near term.
The most commonly misapplied metric for NeoGenomics is the price-to-sales ratio, which obscures the company's underlying profitability challenges by ignoring the high fixed-cost burden and the significant provision for bad debts inherent in the specialized oncology diagnostic business model.
Relying on P/S ratios fails to account for the quality of revenue, specifically the difference between billed amounts and actual collections. Analysts should instead focus on adjusted EBITDA margins and free cash flow conversion to better understand the company's true earning power and its ability to sustain operations without external financing.
Includes 30+ ratios · 26 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying NEO stock.
NeoGenomics, Inc.'s current P/E ratio is -3.5x. The historical average is 56.2x.
NeoGenomics, Inc.'s current EV/EBITDA is 395.5x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 20.4x.
NeoGenomics, Inc.'s return on equity (ROE) is -12.4%. The historical average is -39.4%.
Based on historical data, NeoGenomics, Inc. is trading at a P/E of -3.5x. Compare with industry peers and growth rates for a complete picture.
NeoGenomics, Inc. has 38.8% gross margin and -9.1% operating margin.
NeoGenomics, Inc.'s Debt/EBITDA ratio is 270.6x, indicating high leverage. A ratio above 4x may signal elevated financial risk.